Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients

被引:14
|
作者
Ohuchi, Kentaro [1 ]
Kambayashi, Yumi [1 ]
Hidaka, Takanori [1 ]
Fujimura, Taku [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi, Japan
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
melanoma; PAI-1; TAMs; Anti-PD1; Abs; efficacy; MACROPHAGES; PROMOTES; CELLS;
D O I
10.3389/fonc.2021.798385
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various cancers, including melanomas. Indeed, various pro-tumorigenic functions of PAI-1 in cancer progression and metastasis have been widely reported. Among them, PAI-1 is also reported as a key regulator of PD-L1 expression on melanoma cells through endocytosis, leading to abrogating the efficacy of anti-PD1 antibodies (Abs). These findings suggested that PAI-1 expression might predict the efficacy of anti-PD1 Abs. In this report, the expression and production of PAI-1 in melanoma patients were evaluated, and the immunomodulatory effects of PAI-1 on tumor-associated macrophages were investigated in vitro. Immunohistochemical staining of PAI-1 showed that PAI-1 expression on melanoma cells was significantly decreased in responders compared to non-responders. Moreover, baseline serum levels of PAI-1 were significantly decreased in responders compared to non-responders. Notably, PAI-1 decreased the production of various chemokines from monocyte-derived M2 macrophages in vitro, suggesting that PAI-1 might decrease tumor-infiltrating lymphocytes to hamper the anti-tumor effects of anti-PD1 Abs. These results suggest that baseline serum levels of PAI-1 may be useful as a biomarker for identifying patients with advanced cutaneous melanoma most likely to benefit from anti-melanoma immunotherapy.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Eravacycline improves the efficacy of anti-PD1 immunotherapy via AP1/ CCL5 mediated M1 macrophage polarization in melanoma
    Liu, Nian
    Yan, Mingjie
    Lu, Can
    Tao, Qian
    Wu, Jie
    Zhou, Zhaokai
    Chen, Jing
    Chen, Xiang
    Peng, Cong
    BIOMATERIALS, 2025, 314
  • [22] Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients
    Eikenes, Grethe
    Liszkay, Gabriella
    Balatoni, Timea
    Czirbesz, Kata
    Hunyadi, Karen
    Kozeki, Zsofia
    Kispal, Mihaly Tamas
    Baranyai, Fanni
    Danyi, Timea
    Bocs, Katalin
    Kenessey, Istvan
    CANCERS, 2023, 15 (15)
  • [23] PD-1 inhibitors might limit the development of brain metastases in patients with advanced melanoma
    Marcaillou, Marion
    Linder, Clara
    Chaltiel, Leonor
    Sibaud, Vincent
    Pages, Cecile
    Modesto, Anouchka
    Chira, Ciprian
    Dalmasso, Celine
    Boulinguez, Serge
    Bedane, Christophe
    Meyer, Nicolas
    MELANOMA RESEARCH, 2020, 30 (06) : 580 - 589
  • [24] Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases
    Jacobsoone-Ulrich, Aurelie
    Jamme, Philippe
    Alkeraye, Salim
    Dzwiniel, Veronique
    Faure, Emmanuel
    Templier, Carole
    Mortier, Laurent
    MELANOMA RESEARCH, 2016, 26 (02) : 153 - 156
  • [25] Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy
    Carron, Romain
    Gaudy-Marqueste, Caroline
    Amatore, Florent
    Padovani, Laetitia
    Malissen, Nausicaa
    Balossier, Anne
    Loundou, Anderson
    Bonnet, Nathalie
    Muracciole, Xavier
    Regis, Jean-Marie
    Grob, Jean-Jacques
    EUROPEAN JOURNAL OF CANCER, 2020, 135 : 52 - 61
  • [26] Cordycepin Augments the Efficacy of Anti-PD1 against Colon Cancer
    Chang, Wen-Kuei
    Chen, Yen-Ting
    Lin, Chin-Ping
    Wang, Chia-Jung
    Shieh, Hui-Ru
    Chi, Chih-Wen
    Tsai, Tung-Hu
    Chen, Yu-Jen
    BIOMEDICINES, 2024, 12 (07)
  • [27] Circulating Tumor DNA Early Kinetics Predict Response of Metastatic Melanoma to Anti-PD1 Immunotherapy: Validation Study
    Herbreteau, Guillaume
    Vallee, Audrey
    Knol, Anne-Chantal
    Theoleyre, Sandrine
    Quereux, Gaelle
    Varey, Emilie
    Khammari, Amir
    Dreno, Brigitte
    Denis, Marc G.
    CANCERS, 2021, 13 (08)
  • [28] Anti-PD1 antibodies in patients aged ≥ 75 years with metastatic melanoma: A retrospective multicentre study
    Ridolfi, Laura
    De Rosa, Francesco
    Petracci, Elisabetta
    Tanda, Enrica Teresa
    Marra, Elena
    Pigozzo, Jacopo
    Marconcini, Riccardo
    Guida, Michele
    Cappellini, Gian Carlo Antonini
    Gallizzi, Giulia
    Occelli, Marcella
    Pala, Laura
    Gambale, Elisabetta
    Bersanelli, Melissa
    Galdo, Giovanna
    Cortellini, Alessio
    Morgese, Francesca
    Zoratto, Federica
    Stucci, Luigia Stefania
    Strippoli, Sabino
    Guidoboni, Massimo
    JOURNAL OF GERIATRIC ONCOLOGY, 2020, 11 (03) : 515 - 522
  • [29] Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD1 therapy
    Galus, Lukasz
    Michalak, Michal
    Lorenz, Mateusz
    Stoinska-Swiniarek, Renata
    Tusien Malecka, Daria
    Galus, Agnieszka
    Kolenda, Tomasz
    Leporowska, Ewa
    Mackiewicz, Jacek
    CANCER, 2023, 129 (13) : 2047 - 2055
  • [30] Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy
    Funck-Brentano, Elisa
    Baghad, Bouchra
    Fort, Magali
    Aouidad, Iman
    Roger, Anissa
    Beauchet, Alain
    Otmezguine, Yves
    Blom, Astrid
    Longvert, Christine
    Boru, Blandine
    Saiag, Philippe
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (06) : 1707 - 1714